Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
82 studies found for:    "Rubella"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Rubella Susceptibility in Multiparous Women
Conditions: Rubella;   Vaccine
Intervention:
2 Completed Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second Vaccination
Condition: Measles/Rubella
Intervention: Drug: Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
3 Completed Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Special Drug Use Surveillance of Vaccinees After the First Vaccination
Condition: Measles/Rubella
Intervention: Drug: Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
4 Completed Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella
Conditions: Rubella;   Measles
Intervention: Biological: Double viral (MR) vaccine
5 Completed Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
Condition: Measles; Mumps; Rubella
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762);   Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
6 Completed Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
Conditions: Measles;   Mumps;   Rubella
Intervention: Biological: MMR Vaccine
7 Completed Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older
Conditions: Rubella;   Mumps;   Measles
Interventions: Biological: Priorix®;   Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine
8 Completed Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
Conditions: Rubella;   Mumps;   Measles
Interventions: Biological: Priorix®;   Biological: M-M-R®II;   Biological: Kinrix®;   Biological: Varivax®
9 Completed Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
Conditions: Measles;   Mumps;   Rubella
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762);   Biological: Merck & Co., Inc.'s M-M-R®II, combined measles-mumps-rubella virus vaccine live;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
10 Completed Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)
Conditions: Mumps;   Rubella;   Measles
Intervention: Biological: MMR (Mumps, Measles and Rubella)
11 Completed Coadministration of Measles-rubella and Rotavirus Vaccines
Conditions: Measles Antibody Seroconversion;   Rubella Antibody Seroconversion;   Rotavirus GMT;   Rotavirus IgA Seropositivity
Interventions: Biological: Rotarix vaccine;   Biological: measles-rubella vaccine
12 Completed Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Conditions: Measles;   Rubella;   Mumps;   Varicella
Intervention: Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)
13 Completed Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Conditions: Mumps;   Rubella;   Measles;   Varicella
Intervention: Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)
14 Completed Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Conditions: Mumps;   Varicella;   Rubella;   Measles
Intervention: Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)
15 Completed Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.
Conditions: Measles;   Mumps;   Rubella;   Varicella
Interventions: Biological: MMR Bio-Manguinhos;   Biological: MMR GlaxoSmithKline
16 Active, not recruiting Study of Rubella Immunity. Response to Vaccination of Subjects With Very Low, Equivocal or Undetectable Titers of Rubella Virus Antibodies
Condition: Pregnancy
Intervention: Biological: Determination of Anti-Rubella Antibody, E1
17 Completed Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds
Conditions: Measles;   Varicella;   Mumps;   Rubella
Interventions: Biological: Priorix-Tetra TM (combined measles-mumps-rubella-varicella vaccine);   Biological: GSK Biologicals' 208136, new formulation
18 Completed
Has Results
Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers
Conditions: Japanese Encephalitis;   Measles;   Mumps;   Rubella
Intervention: Biological: Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
19 Completed Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136
Conditions: Measles;   Varicella;   Mumps;   Rubella
Interventions: Biological: PriorixTM;   Biological: VarilrixTM;   Biological: GSK Biologicals' vaccine 208136
20 Completed Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
Conditions: Rubella;   Mumps;   Measles
Intervention: Biological: MMR vaccine (Priorix)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.